—
C+
C+ The full Closelooknet — membership. Open the C+ overview

United Therapeutics Corporation (UTHR) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for UTHR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.35 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How UTHR has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.35 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), United Therapeutics Corporation moved 0.35% on average · correlation 0.10 · higher than 34% of US names
  • Beta, last 3 months 0.40 about the same as over the year
  • On the 10 worst bond days −0.68% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −3.52% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · United States · 5 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against UTHR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — United Therapeutics Corporation

UTHR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
United Therapeutics develops and sells medicines for pulmonary arterial hypertension, a disease that narrows the lung's blood vessels, through drugs such as Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram and Adcirca, plus the cancer drug Unituxin. It also runs an early research programme building gene-edited pig organs, including kidneys and hearts, aimed at future transplant use. The company is based in Silver Spring, Maryland, and trades in the United States.
Where it sits in the stack
United Therapeutics carries no seat in Rubin, our AI infrastructure index. In the diary's broader universe it sits in the Healthcare sector, within the Drug Manufacturers – Specialty & Generic industry.
Who it is priced against
Closelooknet does not carry a peer group for United Therapeutics. The market names Liquidia Corporation as a comparison, since it also sells an inhaled treprostinil therapy competing directly with Tyvaso.
Why Closelooknet tracks it
United Therapeutics holds a seat in the Russell 1000. The diary does not yet carry a Closelooknet score for it, and it has not appeared in any edition or quote so far.
What the diary watches
The diary watches whether inhaled or oral rivals erode Remodulin and Tyvaso sales, and whether the xenotransplantation research moves toward any clinical use.

United Therapeutics Corporation (UTHR) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: initiation by Goldman Sachs, 2026-09-24

The Street on this name

Analyst actions and the latest print for UTHR from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Initiation Goldman Sachs — at Sell Initiated to Sell from Neutral 2026-09-24

1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is United Therapeutics Corporation (UTHR)?

United Therapeutics Corporation trades as UTHR on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is UTHR in a Closelooknet index?

Not currently — United Therapeutics Corporation is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does UTHR trade against its moving averages?

Mixed moving-average stack: Trades -7.1% vs the 50-day and -9.3% vs the 200-day average, 22% below the 52-week high and +16.2% off the 52-week low; a death cross printed 12 sessions ago. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does United Therapeutics Corporation trade when bond yields rise?

Over the past year United Therapeutics Corporation had a beta of 0.35 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 34% of US names. On the 10 sessions in which long bonds fell most it moved −0.68% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does United Therapeutics Corporation do?

United Therapeutics develops and sells medicines for pulmonary arterial hypertension, a disease that narrows the lung's blood vessels, through drugs such as Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram and Adcirca, plus the cancer drug Unituxin. It also runs an early research programme building gene-edited pig organs, including kidneys and hearts, aimed at future transplant use. The company is based in Silver Spring, Maryland, and trades in the United States. Closelooknet does not carry a peer group for United Therapeutics. The market names Liquidia Corporation as a comparison, since it also sells an inhaled treprostinil therapy competing directly with Tyvaso.

Where does United Therapeutics Corporation sit in the AI build-out?

United Therapeutics carries no seat in Rubin, our AI infrastructure index. In the diary's broader universe it sits in the Healthcare sector, within the Drug Manufacturers – Specialty & Generic industry. United Therapeutics holds a seat in the Russell 1000. The diary does not yet carry a Closelooknet score for it, and it has not appeared in any edition or quote so far.

What has Wall Street done on United Therapeutics Corporation recently?

The most recent analyst action on United Therapeutics Corporation on the Closelooknet wire is a initiation by Goldman Sachs on 2026-09-24 (at Sell). 1 action on the analyst wire since 2026-08-13: 1 initiation. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for UTHR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.